• Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Neoimmunetech Inc.

Headquarters: Rockville, MD, United States
Website: http://www.neoimmunetech.com...
Year Founded: 2014
Status: Public
Industry Sector: HealthTechnology
CEO: Luke Oh, PhD
Number Of Employees: 52
Enterprise Value: $59,506,086
PE Ratio: -2.3
Exchange/Ticker 1: KOSDAQ:950220
Exchange/Ticker 2: N/A
Latest Market Cap: $72,724,288

BioCentury | May 31, 2024
Product Development

Immunotherapies break into cold colorectal cancers at ASCO

Data from Regeneron, Agenus and others highlight immuno-oncology progress in genetically stable colorectal cancer 
Read More
BioCentury | May 14, 2024
Data Byte

The diverse modalities targeting B7-H3

ADCs against the target have raised safety concerns, but companies are hitting B7-H3 with other modalities
Read More
BioCentury | Apr 30, 2024
Management Tracks

Innovent hires Gracell vet Samuel Zhang as CBO

Plus: CEO changes at Lexicon, Avacta and Sphere Fluidics, and updates from Generate, Charm, ViaNautis and more
Read More
BioCentury | Jan 17, 2024
Management Tracks

CEO departures at Aclaris and Vaxart

Plus: David Pyrce named CEO at Cognigenics, and updates from NextPoint, Hookipa, NeoImmuneTech, Neurogene, Paratek and Aspen
Read More
BioCentury | Jul 20, 2022
Management Tracks

Gur, Clifford to lead U.K.’s new Advanced Research and Invention Agency

Plus restructuring at Invitae brings new CEO, and updates from Codexis, Compass, Tectonic and more
Read More
BioCentury | Jun 17, 2022
Discovery & Translation

Scalable method to measure SARS-CoV-2 T cell immunity; plus therapies from NeoImmune, Exavir and more

BioCentury’s roundup of translational news
Read More
BioCentury | Aug 27, 2021
Management Tracks

Pfizer names McKinsey vet Malik to succeed Young

Plus: Lonza, Renovacor, Lilly, Adamis, NeoImmuneTech and more
Read More
BioCentury | Aug 19, 2021
Product Development

Dealmaking and bispecifics cut trail to IPO for Y-Biologics

Korea Spotlight: Y-Biologics’ in-house antibody technology key to series of global partnerships 
Read More
BioCentury | Mar 6, 2021
Management Tracks

Winter to lead BeiGene’s European commerical ops; plus Dyne, Axcella, Prometheus and more

BeiGene Ltd. (NASDAQ:BGNE; HKEX:6160) hired Gerwin Winter as SVP and head of commercial for Europe. Winter was previously SVP and head of Europe at Portola Pharmaceuticals Inc. before its acquisition
Read More
BioCentury | Feb 1, 2020
Company News

Management tracks: Trio of female exec appointments; plus FDA, Cell and Gene Therapy Catapult, SutroVax, Lundquist Institute, RedShift, NeoImmuneTech and more

Read More
Items per page:
1 - 10 of 13
Help Center
Username
Request Training
Submit Data Correction
Ask a Question
Elevio by Dixa